EPAT General Discussion, page-70

I think the buying/selling atm isn't really indicative of what the price may be in 2-3 months. Alot can change. Their development path and commercialisation path is strong with the right people and entities behind it. The results from the May trials will be interesting and more encompassing than the first trial results.

Let's all calm down, be realistic and hope for the best...If the product continues to work and trials keep indicating this, it will do well. If there is demand for the product, it will do well. The interesting thing will be whether there is alot of demand for the product when they approach commercialisation.

I would also like to know how the app performs when used on a patient in pain against the same patient pretending to be in pain (not a dementia patient obviously) but a cognatively alert person who is in pain vs the same person grimacing and/squinting to appear to be in pain.

Imo they have delineated this in the development of their product but would like confirmation, unless I have missed something fundamental here?? Obviously there would be great potential there for court compensation claims etc but this component of the app still needs to be able to distinguish real pain vs apparent 'fake' pain in all end users.

Is anyone able to shed light on this?